Skip to main content

dupilumab (Dupixent®)

 

Following a limited submission

AWMSG advice

Status: Recommended with restrictions

Dupilumab (Dupixent®) is recommended as an option for restricted use within NHS Wales. Dupilumab (Dupixent®) is licensed for the treatment of moderate-to-severe atopic dermatitis in adolescents ≥ 12 to < 18 years who are candidates for systemic therapy. Dupilumab (Dupixent®) is restricted for the treatment of moderate-to-severe atopic dermatitis in adolescents ≥ 12 to < 18 years who are candidates for systemic therapy, only if the disease has not responded to at least one other systemic therapy, or these are contraindicated or not tolerated. Dupilumab (Dupixent®) is not recommended for use within NHS Wales outside of this subpopulation. This recommendation applies only in circumstances where the approved Patient Access Scheme (PAS) is utilised or where the list/contract price is equivalent or lower than the PAS price.

 Final Recommendation: dupilumab (Dupixent)4089 (PDF, 354Kb)
 Appraisal Report: dupilumab (Dupixent) 4089 (PDF, 276Kb)

Medicine details

Medicine name dupilumab (Dupixent®)
Formulation 300 mg solution for injection and 200 mg solution for injection
Reference number 4089
Indication

Treatment of moderate-to-severe atopic dermatitis in adolescents ≥ 12 to < 18 years of age who are candidates for systemic therapy

Company Sanofi
BNF chapter Skin
Submission type Limited
Status Recommended with restrictions
Advice number 1419
NMG meeting date 09/10/2019
AWMSG meeting date 13/11/2019
Date of issue 28/11/2019
Commercial arrangement PAS